- Home
- FEMY vs BOWN Comparison
FEMY vs BOWN Comparison
Compare FEMY & BOWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FEMY
- BOWN
- Stock Information
- Founded
- FEMY 2004
- BOWN 2023
- Country
- FEMY United States
- BOWN United States
- Employees
- FEMY N/A
- BOWN N/A
- Industry
- FEMY Medical/Dental Instruments
- BOWN
- Sector
- FEMY Health Care
- BOWN
- Exchange
- FEMY Nasdaq
- BOWN Nasdaq
- Market Cap
- FEMY 31.9M
- BOWN 28.5M
- IPO Year
- FEMY 2021
- BOWN 2023
- Fundamental
- Price
- FEMY $0.91
- BOWN N/A
- Analyst Decision
- FEMY Strong Buy
- BOWN
- Analyst Count
- FEMY 3
- BOWN 0
- Target Price
- FEMY $8.67
- BOWN N/A
- AVG Volume (30 Days)
- FEMY 280.4K
- BOWN 2.7K
- Earning Date
- FEMY 08-07-2025
- BOWN 01-01-0001
- Dividend Yield
- FEMY N/A
- BOWN N/A
- EPS Growth
- FEMY N/A
- BOWN N/A
- EPS
- FEMY N/A
- BOWN 0.02
- Revenue
- FEMY $1,699,232.00
- BOWN N/A
- Revenue This Year
- FEMY $231.84
- BOWN N/A
- Revenue Next Year
- FEMY $245.28
- BOWN N/A
- P/E Ratio
- FEMY N/A
- BOWN $206.51
- Revenue Growth
- FEMY 61.97
- BOWN N/A
- 52 Week Low
- FEMY $0.69
- BOWN $2.71
- 52 Week High
- FEMY $1.80
- BOWN $19.77
- Technical
- Relative Strength Index (RSI)
- FEMY 50.88
- BOWN 49.69
- Support Level
- FEMY $0.90
- BOWN $8.70
- Resistance Level
- FEMY $0.99
- BOWN $10.20
- Average True Range (ATR)
- FEMY 0.07
- BOWN 0.42
- MACD
- FEMY 0.01
- BOWN 0.04
- Stochastic Oscillator
- FEMY 39.48
- BOWN 79.04
About FEMY Femasys Inc.
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
About BOWN Bowen Acquisition Corp
Bowen Acquisition Corp is a blank check company.